{"id":3311,"date":"2018-08-17T07:47:41","date_gmt":"2018-08-17T07:47:41","guid":{"rendered":"http:\/\/www.sfogveckan.se\/?page_id=3311"},"modified":"2018-08-17T07:47:41","modified_gmt":"2018-08-17T07:47:41","slug":"industrisponsrat-symposium","status":"publish","type":"page","link":"https:\/\/appsinmed.com\/sfog2018\/industrisponsrat-symposium\/","title":{"rendered":"Industrisponsrat symposium"},"content":{"rendered":"

[et_pb_section bb_built=”1″][et_pb_row _builder_version=”3.2.2″ background_color=”#1096d4″][et_pb_column type=”4_4″][et_pb_text _builder_version=”3.2.2″]<\/p>\n

INDUSTRISPONSRAT SYMPOSIUM<\/strong><\/span><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row][et_pb_column type=”1_2″][et_pb_text _builder_version=”3.12.1″]<\/p>\n

M\u00c5N KL.12.15 – 13.30<\/span>
\n<\/b><\/span><\/p>\n

Avia Pharma<\/span><\/strong><\/span><\/p>\n

F\u00f6rel\u00e4sare: Angelica Lind\u00e9n Hirschberg och Stefan Arver
\n<\/span>Lokalt DHEA vid vaginal atrofi \u2013 vad tillf\u00f6r androgener?\u201d<\/span><\/p>\n

[\/et_pb_text][et_pb_text _builder_version=”3.12.1″]<\/p>\n

ONS KL. 12.00 – 13.15<\/strong><\/span><\/p>\n

Gedeon Richter<\/span><\/strong><\/span><\/p>\n

F\u00f6rel\u00e4sare:\u00a0Pablo Arriagada, MD<\/span>
\nModerator:\u00a0<\/span>Kristina Gemzell Danielsson<\/span><\/p>\n

How do we proceed with ESMYA\u00ae?<\/span>
\nGuidance of ESMYA\u00ae in clinical practice after<\/span>
\nthe EMA decision.<\/b><\/span><\/p>\n

 <\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_2″][et_pb_text _builder_version=”3.12.1″]<\/p>\n

M\u00c5N KL.17.05 – 17.35<\/strong><\/span><\/p>\n

Natural Cycles<\/strong>
\n<\/span><\/p>\n

Moderator: Kristina Gemzell-Danielsson, Professor i obstetrik och gynekologi,
\nKarolinska Institutet och Karolinska Universitetssjukhuset
\n<\/span><\/p>\n

1705-1720\u00a0 –\u00a0<\/span>Preventivmedel – kvinnors \u00f6nskem\u00e5l och \u00f6verv\u00e4ganden
\n<\/b>Ingrid S\u00e4\u00e4v, PhD, \u00d6verl\u00e4kare, Norrt\u00e4lje sjukhus<\/span><\/p>\n

\u00a0<\/span>1720-1735\u00a0 –\u00a0<\/span>Evidens kring anv\u00e4ndningen av preventivmedelsappar<\/b><\/p>\n

\n
\n
Helena Kopp Kallner, \u00d6verl\u00e4kare, docent, Kvinnokliniken, Danderyds Sjukhus<\/span><\/div>\n<\/div>\n<\/div>\n

[\/et_pb_text][et_pb_text _builder_version=”3.12.1″]<\/p>\n

TIS KL.17.05 – 17.35<\/strong><\/span><\/p>\n

Peptonic Medical<\/span><\/strong><\/span><\/p>\n

F\u00f6rel\u00e4sare:\u00a0Docent Aino Fianu Jonasson, Karolinska Institutets kvinnoforskningsenhet.<\/span><\/p>\n

<\/b>VagiVital \u2013 Ett alternativ f\u00f6r de som inte vill, kan eller f\u00e5r anv\u00e4nda hormoner f\u00f6r behandling av vaginal atrofi
\n<\/span>Resultat fr\u00e5n multicenterstudie vid Karolinska sjukhuset, Akademiska sjukhuset i Uppsala samt Norrlands universitetssjukhus.<\/span><\/p>\n

[\/et_pb_text][et_pb_text _builder_version=”3.12.1″]<\/p>\n

ONS KL.16.50 – 17.20<\/strong><\/span><\/p>\n

Solann<\/span><\/strong><\/span><\/p>\n

F\u00f6rel\u00e4sare: Dr. Ilan Baram<\/span><\/p>\n

“The next generation IUD:\u00a0IUB\u2122\u00a0Intrauterine Ball”\/\u00a0“N\u00e4sta generations IUD: IUB \u2122 Intrauterine Ball”<\/p>\n

<\/span>The IUB\u2122 \u00a0is the first and only 3D spherical IUD, which physiologically adapts\u00a0to the shape of the uterus. The size and shape of the IUB\u2122 minimize the\u00a0possibility of irritation to the endometrium, risk of perforation and malpositioning.<\/i><\/b><\/span><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

[et_pb_section bb_built=”1″][et_pb_row _builder_version=”3.2.2″ background_color=”#1096d4″][et_pb_column type=”4_4″][et_pb_text _builder_version=”3.2.2″] INDUSTRISPONSRAT SYMPOSIUM [\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row][et_pb_column type=”1_2″][et_pb_text _builder_version=”3.12.1″] M\u00c5N KL.12.15 – 13.30 Avia Pharma F\u00f6rel\u00e4sare: Angelica Lind\u00e9n Hirschberg och Stefan Arver Lokalt DHEA vid vaginal atrofi \u2013 vad tillf\u00f6r androgener?\u201d [\/et_pb_text][et_pb_text _builder_version=”3.12.1″] ONS KL. 12.00 – 13.15 Gedeon Richter F\u00f6rel\u00e4sare:\u00a0Pablo Arriagada, MD Moderator:\u00a0Kristina Gemzell Danielsson How do we proceed with ESMYA\u00ae? Guidance […]<\/p>\n","protected":false},"author":34,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"

[et_pb_section bb_built=\"1\"][et_pb_row][\/et_pb_row][\/et_pb_section]<\/p>","_et_gb_content_width":""},"_links":{"self":[{"href":"https:\/\/appsinmed.com\/sfog2018\/wp-json\/wp\/v2\/pages\/3311"}],"collection":[{"href":"https:\/\/appsinmed.com\/sfog2018\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/appsinmed.com\/sfog2018\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/appsinmed.com\/sfog2018\/wp-json\/wp\/v2\/users\/34"}],"replies":[{"embeddable":true,"href":"https:\/\/appsinmed.com\/sfog2018\/wp-json\/wp\/v2\/comments?post=3311"}],"version-history":[{"count":39,"href":"https:\/\/appsinmed.com\/sfog2018\/wp-json\/wp\/v2\/pages\/3311\/revisions"}],"predecessor-version":[{"id":3395,"href":"https:\/\/appsinmed.com\/sfog2018\/wp-json\/wp\/v2\/pages\/3311\/revisions\/3395"}],"wp:attachment":[{"href":"https:\/\/appsinmed.com\/sfog2018\/wp-json\/wp\/v2\/media?parent=3311"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}